Addex Therapeutics (ADXN.SW) trades at CHF 0.05 as we head into its earnings announcement on 09 Mar 2026. ADXN.SW stock rose 8.70% on volume 199946.00 in the latest session, with the market closed on our reporting day, 06 Mar 2026. We expect the report to focus on cash runway, clinical updates for Dipraglurant, and partner milestone timing. This earnings spotlight frames valuation, pipeline catalysts, and short-term trading risk for Swiss-listed Addex on the SIX exchange.

ADXN.SW stock: Earnings context and timetable

Earnings are scheduled for 09 Mar 2026, with Addex due to report clinical progress and cash position. ADXN.SW stock carries limited revenue history, so investors will watch guidance and trial timelines. Management updates could move the share price more than routine metrics because the company is development-stage and partnership news matters.

Financial snapshot and valuation for ADXN.SW stock

Market cap stands at CHF 7543595.00 with shares outstanding 150871899.00. Trailing EPS is -0.06 and P/E reads -0.83, reflecting negative earnings. Price-to-book is 0.87 and cash per share is 0.02, giving a current ratio near 2.01. These figures show deep valuation tied to pipeline value rather than sales.

Clinical pipeline and catalysts affecting ADXN.SW stock

Addex’s lead program Dipraglurant targets levodopa-induced dyskinesia in Parkinson’s disease. Partnerships with Janssen and Indivior provide validation and milestone potential. Any timing update on Phase II/III or licensing milestones will be the primary upside trigger for ADXN.SW stock.

Technical and trading picture for ADXN.SW stock

The share traded between CHF 0.0432 and CHF 0.05 on the last session, with volume 199946.00 versus average 174463.00. RSI is 34.97, suggesting the stock is near oversold territory. The 50-day average is CHF 0.05 and the 200-day average is CHF 0.06, indicating a weak trend on a low-price base.

Meyka AI rates ADXN.SW with a score out of 100 and forecast

Meyka AI rates ADXN.SW with a score out of 100: 66.83 (Grade B) — HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst inputs. Meyka AI’s forecast model projects a yearly price of CHF 0.03, versus the current CHF 0.05, implying -40.00% downside. Forecasts are model-based projections and not guarantees.

Risks and what investors should watch for ADXN.SW stock

Primary risks are clinical failure, thin liquidity, and finite cash runway. Sector headwinds matter; the Healthcare sector YTD is -3.08%, which can amplify volatility. Watch cash disclosures, milestone guidance, and partner announcements closely around earnings.

Final Thoughts

Key takeaways for ADXN.SW stock ahead of the 09 Mar 2026 earnings are clear. Addex trades at CHF 0.05 on SIX with limited revenue and negative EPS -0.06, so the report will focus on clinical progress and cash. Meyka AI’s model projects a one-year price of CHF 0.03, implying -40.00% versus today; scenario price targets for investors include a conservative CHF 0.02, base CHF 0.05, and optimistic CHF 0.10. These targets show a wide risk-reward skew and reinforce a cautious stance. We advise watching management commentary on milestone timing and partner payments, because clinical or licensing updates are the likeliest near-term catalysts. All forecasts are model-based and not guarantees, and this analysis is informational only.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.